ODG adopts formulary updates effective November 1, 2024

Posted on
Shelf of prescription pill bottles

ODG by MCG has adopted updates to its ODG Drug Formulary, which includes U.S. Food and Drug Administration (FDA) approved drugs listed by generic and/or brand names that are commonly prescribed for workplace injuries. The changes to Appendix A of the formulary can be categorized in one of three ways: new entry, updated entry, or removed entry. All the updates are effective November 1, 2024.

Several states have adopted the ODG formulary for use in their workers’ compensation systems. Examples include Indiana, Montana, and Texas, among several others. These states, to varying degrees, require some type of prior authorization for medications listed as “N” status on the ODG formulary and in some cases for medications not listed on the ODG formulary.

MyMatrixx will make the following changes to our formularies in accordance with the ODG updates and deadline.

Appendix A ODG Formulary Updates

New Entries
  • Fondaparinux (brand name Arixtra); an anticoagulant and new N drug
  • A distinct formulation of opioid oxycodone, brand name Roxybond, a new N drug
Updated Entry
  • New formulation of oxycodone (brand name Oxaydo); changing from a Y drug to an N drug
Removed Entries
  • Intrathecal clonidine, an N drug
  • Carbidopa/levodopa, a Y drug
  • Ranitidine, an N drug
  • Didanosine (including the ER formulation), an N drug
  • Hepatitis B immune globulin, a Y drug (Reference brand HepaGam B NovaPluss ONLY. Other formulations will remain on Appendix A as Y drugs.)

About ODG

ODG by MCG offers highly configurable, industry-specific medical treatment and return-to-work solutions, which are used for managing workers’ compensation, disability, and auto liability claim outcomes with evidence-based, data-driven decision support.

MyMatrixx Actions

MyMatrixx maintains ODG-based formularies and will update them in accordance with the above changes. For any changes, please reach out to your MyMatrixx account team.

Back to PharmaWatch